Bio Techne Corp Stock Today
| TECH Stock | USD 61.86 0.26 0.42% |
PerformanceFair
| Odds Of DistressLow
|
Bio Techne is trading at 61.86 as of the 20th of October 2025. This is a 0.42% increase since the beginning of the trading day. The stock's open price was 61.6. Bio Techne has only a 6 % chance of going through financial distress over the next few years but had a somewhat fair performance during the last 90 days. Note, on September 3, 2025, Representative April Delaney of US Congress acquired under $15k worth of Bio Techne Corp's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of February 1989 | Category Healthcare | Classification Health Care |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. The company has 155.69 M outstanding shares of which 5.38 M shares are at this time shorted by private and institutional investors with about 2.19 trading days to cover. More on Bio Techne Corp
Moving together with Bio Stock
Moving against Bio Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Bio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Charles Kummeth | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Techfinancials Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBio Techne can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bio Techne's financial leverage. It provides some insight into what part of Bio Techne's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bio Techne Corp (TECH) is traded on NASDAQ Exchange in USA and employs 3,100 people. Bio Techne is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.63 B. Bio Techne Corp conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 155.69 M outstanding shares of which 5.38 M shares are at this time shorted by private and institutional investors with about 2.19 trading days to cover.
Bio Techne Corp currently holds about 247.03 M in cash with 287.56 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.3.
Check Bio Techne Probability Of Bankruptcy
Ownership AllocationThe majority of Bio Techne Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bio Techne Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bio Techne. Please pay attention to any change in the institutional holdings of Bio Techne Corp as this could imply that something significant has changed or is about to change at the company. On September 3, 2025, Representative April Delaney of US Congress acquired under $15k worth of Bio Techne Corp's common stock.
Check Bio Ownership Details
Bio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Mairs & Power Inc | 2025-06-30 | 2.7 M | |
| Champlain Investment Partners, Llc | 2025-06-30 | 2.7 M | |
| Mackenzie Investments | 2025-06-30 | 2.6 M | |
| Neuberger Berman Group Llc | 2025-06-30 | 2.5 M | |
| Citadel Advisors Llc | 2025-06-30 | 2.5 M | |
| Sumitomo Mitsui Trust Group Inc | 2025-06-30 | 2.3 M | |
| Rgm Capital Llc | 2025-06-30 | 2.2 M | |
| Bank Of New York Mellon Corp | 2025-06-30 | 1.9 M | |
| Norges Bank | 2025-06-30 | 1.9 M | |
| Vanguard Group Inc | 2025-06-30 | 18.4 M | |
| Blackrock Inc | 2025-06-30 | 12.2 M |
Bio Techne Corp Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bio Techne market risk premium is the additional return an investor will receive from holding Bio Techne long position in a well-diversified portfolio.
| Mean Deviation | 2.12 | |||
| Semi Deviation | 2.5 | |||
| Standard Deviation | 2.98 | |||
| Variance | 8.87 |
Bio Stock Against Markets
Bio Techne Corporate Management
| Lynne Hohlfeld | Senior Division | Profile | |
| Steven Crouse | Senior Division | Profile | |
| Gerry Andros | Vice Marketing | Profile | |
| Bernie Andruss | Senior Division | Profile | |
| Kim Kelderman | Pres Genomics | Profile | |
| Dylan Malayter | Senior Division | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Dividend Share 0.32 | Earnings Share 0.46 | Revenue Per Share | Quarterly Revenue Growth 0.036 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.